Avenue Therapeutics | 10-Q: Q2 2024 Earnings Report
Avenue Therapeutics | 8-K: Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Avenue Therapeutics | 8-K: Current report
Avenue Therapeutics | 8-K: Current report
Avenue Therapeutics | 10-Q: Q1 2024 Earnings Report
Avenue Therapeutics | 8-K: Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics | 8-K: Current report
Avenue Therapeutics | EFFECT: Others
Avenue Therapeutics | 424B5: Prospectus
Avenue Therapeutics | 424B3: Prospectus
Avenue Therapeutics | CORRESP: CORRESP
Avenue Therapeutics | UPLOAD: Others
Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Avenue Therapeutics | DEFA14A: Others
Avenue Therapeutics | DEF 14A: Definitive information statements
Avenue Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Robert Davidow(2.9%)
Avenue Therapeutics | 8-K: Current report
Avenue Therapeutics | 8-K: Current report
Avenue Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Fortress Biotech, Inc.(8.0%)
No Data
No Data